

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine



Sleep Disorders

Guest Editor—Angelos Halaris, MD, PhD

INTRODUCTION

**Psychiatric Comorbidity and Pharmacotherapy
in Sleep Disorders**

A. Halaris

ORIGINAL RESEARCH

**Psychological Status and Levels of Sleepiness-Alertness
Among Patients With Insomnia**

L.D. Rosenthal and R.M. Meixner

ORIGINAL RESEARCH

**Melatonin and Jet Lag Syndrome:
Experimental Model and Clinical Implications**

G.F. Oxenkrug and P.J. Requintina

REVIEW

A Review of Common Sleep Disorders

A.C. Ricbert and A.S. Baran

REVIEW

Obstructive Sleep Apnea and Depression

A.S. Baran and A.C. Ricbert

REVIEW

**Narcolepsy: Differential Diagnosis or
Etiology in Some Cases of Bipolar Disorder
and Schizophrenia?**

A.B. Douglass

REVIEW

Rhythmic Movement Disorder in Children

T.F. Hoban

PSRST STD
US POSTAGE
PAID
HANOVER NH
PERMIT #192

*****3-DIGIT 871
P 1751
5
63567033219 NHC023
PLT 14
33126

MICHAEL O FLAHERAN, MD
507 TULARE PL NE
ALBUQUERQUE MN 57106-1344

CNS Spectrums
c/o PPS Medical Marketing Group
264 Passaic Ave.
Fairfield, NJ 07004-2595

CHANGE SERVICE REQUESTED



CNS Spectrums is an
Index Medicus journal.

Author Guidelines

Introduction

CNS Spectrums is an *Index Medicus* journal that publishes original scientific literature and reviews on a wide variety of neuroscientific topics of interest to the clinician. *CNS Spectrums* will publish 12 issues in 2003. As the immense prevalence of comorbid diseases among patients seen by psychiatrists and neurologists increases, these physicians will jointly diagnose and treat the neuropsychiatrically ill. Our mission is to provide these physicians with an editorial package that will enhance and increase their understanding of neuropsychiatry; therefore, manuscripts that address crossover issues germane to neurology and psychiatry will be given immediate priority.

Scope of Manuscripts

CNS Spectrums will consider the following types of articles for publication:

Original Reports: Original reports present methodologically sound original data.

Reviews: Reviews are overview articles that summarize and synthesize the literature on various topics in a scholarly and clinically relevant fashion. Suitable topics include mood disorders, schizophrenia and related disorders, personality disorders, substance-use disorders, anxiety disorders, neuroscience, psychosocial aspects of psychiatry, child psychiatry, geriatric psychiatry, and other topics of interest to clinicians. Original flowcharts designed to aid the clinician in diagnosis and treatment will be considered for publication in reviews and are encouraged.

Case Reports: Single or multiple case reports will be considered for publication.

Letters to the Editor: Letters will be considered for publication.

Manuscript Submission

General information: Two copies of the manuscript with a letter on the author's letterhead should be submitted to Jack M. Gorman, Editor (or, in Europe, to Joseph Zohar, International Editor), c/o MBL Communications, 333 Hudson Street, 7th Floor, New York, NY 10013; (F) 212.328.0600. Authors are also required to submit their manuscripts on computer disk in Microsoft Word format. Disks should be labeled with the word processing program, title of paper, and lead author's name. Accepted manuscripts and letters will be edited for clarity and style.

Letters of permission to reproduce previously published material: All material reproduced from previously published copyrighted material must be accompanied by a letter of permission from the copyright holder. All such material should include a full credit line (eg, in the figure or table legend) acknowledging the original source. Any citation of unpublished material or personal communication should also be accompanied by a letter of permission for anyone who is not an author of the paper.

Peer review: Authors must provide five names of particularly qualified potential reviewers with no conflict of interest in reviewing the work. Contact information, including complete address, phone, fax numbers, E-mail address, and affiliations, should be included. The corresponding author will be notified by the editors when a decision regarding acceptance has been made. Peer review is anonymous.

Manuscript Preparation

Length: Reviews and Original Reports should not exceed 5,000 words (excluding References). Letters should not exceed 1,500 words. Single Case Reports should not exceed 3,750 words and may be submitted with a photograph, if applicable. Diagnostic/treatment algorithms (see Reviews) should contain an extensive introduction, flowchart or series of graphs that fill 8–12 journal pages, and a concise summary.

Spacing: One space should be left after commas and periods. Manuscripts should be double-spaced.

Abstract: Authors must provide a brief abstract.

References: American Medical Association style. See the following examples:

1. Jones J. Necrotizing *Candida* esophagitis. *JAMA*. 1980;244:2190-2191.
2. Stryer L. *Biochemistry*. 2nd ed. San Francisco, Calif: WH Freeman Co; 1980:559-596.

Continuing Medical Education: Authors must submit four multiple-choice questions (two Type A and two Type K), with answers.

Copyright: Materials are accepted for exclusive publication in *CNS Spectrums* and become the property of *CNS Spectrums*. Permission to reproduce material must be obtained from the publisher.

Disclosure of Commercial Interests

Authors must include a statement about all forms of support, including grant and drug company support. Such information may, at the editor's discretion, be shared with reviewers. If the article is accepted for publication, the editors will consult with the authors as to whether this information should be included in the published paper.

Submission Checklist

- Original manuscript plus one copy, with cover letter on author's letterhead
- Copies of permission letters to reproduce previously published and unpublished material
- A brief abstract of the article
- Four CME multiple-choice questions with answers
- Disk labeled with the word processing program, title of paper, and lead author's name
- Names and addresses of five potential reviewers





Time for wakefulness

A unique wake-promoting agent

PROVIGIL promotes daytime wakefulness, improving patients' ability to participate in daily activities—with no effect on nighttime sleep.¹⁻³

Long-term safety

The long-term safety profile of PROVIGIL has been demonstrated for up to 136 weeks.⁴

PROVIGIL was generally well tolerated. Most frequently reported adverse events in clinical trials were headache, nausea, nervousness, anxiety, infection, and insomnia. Most adverse events were mild to moderate. PROVIGIL may interact with drugs that inhibit, induce, or are metabolized by cytochrome P450 isoenzymes.

Dosing

Recommended dose for PROVIGIL is 200 mg taken orally once daily in the morning. Both PROVIGIL doses, 200 mg and 400 mg QD, were effective.

PROVIGIL is indicated to improve wakefulness in patients with excessive daytime sleepiness associated with narcolepsy.

References: 1. PROVIGIL full prescribing information. 2. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. *Ann Neurol.* 1998;43:88-97. 3. US Modafinil in Narcolepsy Multicenter Study Group. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. *Neurology.* 2000;54:1166-1175. 4. Data on file, Cephalon, Inc.

PROVIGIL[®]

(MODAFINIL)[®]

Tablets

Wake up to life.[™]

Please see brief summary of prescribing information on adjacent page.
For more information, call 1-800-896-5855 or visit our Website at www.PROVIGIL.com.

CNS SPECTRUMS[®]

The International Journal of Neuropsychiatric Medicine

EDITOR

Jack M. Gorman, MD
Mt. Sinai School of Medicine
New York, NY

ASSOCIATE AND FOUNDING EDITOR

Eric Hollander, MD
Mt. Sinai School of Medicine
New York, NY

INTERNATIONAL EDITOR

Joseph Zohar, MD
Chaim Sheba Medical Center
Tel Hashomer, Israel

MID-ATLANTIC EDITOR

Dan J. Stein, MD, PhD
University of Stellenbosch
Tygerberg, South Africa

FAR EAST EDITOR

Shigeto Yamawaki, MD, PhD
Hiroshima University School
of Medicine
Hiroshima, Japan

CONTRIBUTING WRITERS

Alp Sinan Baran, MD
Alan B. Douglass, MD
Angelos Halaris, MD, PhD
Timothy F. Hoban, MD
Gregory F. Oxenkrug, MD, PhD
Allen C. Richert, MD
Michael Trimble, MD

BOARD OF ADVISORS

NEUROLOGISTS

Mitchell F. Brin, MD
Mount Sinai School of Medicine
New York, NY

Jeffrey L. Cummings, MD
University of California
Los Angeles, CA

Mark George, MD
Medical University of South Carolina
Charleston, SC

Charles Warren Olanow, MD, FRCP
Mt. Sinai School of Medicine
New York, NY

Steven George Pavlakis, MD
Maimonides Medical Center
Brooklyn, NY

Michael Trimble, MD
National Hospital for Neurology
and Neurosurgery
London, United Kingdom

PSYCHIATRISTS

Margaret Altemus, MD
Cornell University Medical Center
New York, NY

Dennis S. Charney, MD
Yale University
New Haven, CT

Dwight L. Evans, MD
University of Pennsylvania
Philadelphia, PA

Siegfried Kasper, MD
University of Vienna
Vienna, Austria

Martin B. Keller, MD
Brown University
Providence, RI

Lorin M. Koran, MD
Stanford University Medical School
Stanford, CA

Yves Lecrubier, MD
Hôpital de la Salpêtrière
Paris, France

Donatella Marazziti, MD
University of Pisa
Pisa, Italy

Herbert Y. Meltzer, MD
Vanderbilt University Medical Center
Nashville, TN

Stuart A. Montgomery, MD
St. Mary's Hospital Medical School
London, United Kingdom

Charles B. Nemeroff, MD, PhD
Emory University School of Medicine
Atlanta, GA

Humberto Nicolini, MD, PhD
National Mexican Institute of Psychiatry
Mexico City, Mexico

Katharine A. Phillips, MD
Brown University
Providence, RI

Harold A. Pincus, MD
Western Psychiatric Institute & Clinic
RAND-University of Pittsburgh Health
Institute, Pittsburgh, PA

Scott L. Rauch, MD
Massachusetts General Hospital
Charlestown, MA

Alan Schatzberg, MD
Stanford University Medical School
Stanford, CA

Stephen Stahl, MD, PhD
University of California, San Diego
San Diego, California

Norman Sussman, MD
New York University Medical School
New York, NY

Karen D. Wagner, MD, PhD
University of Texas at Galveston
Galveston, Texas

Herman G.M. Westenberg, MD
University Hospital Utrecht
Utrecht, The Netherlands

Stuart Yudofsky, MD
Baylor College of Medicine
Houston, TX

MBL COMMUNICATIONS Corporate Staff

CEO & PUBLISHER

Darren L. Brodeur

MANAGING EDITOR

Christopher Naccari

SENIOR EDITOR

Deborah Hughes

DEPUTY SENIOR EDITOR

José R. Ralat

ACQUISITIONS EDITOR

Lisa Arrington

PRODUCTION MANAGER

Lila Moses

GRAPHIC DESIGNER

Anthony J. Korsak

DESIGNER, MULTIMEDIA

Michael Mosley

CONTROLLER

John Spano

SENIOR ACCOUNT MANAGER

Robert Reed

CME PROJECTS DIRECTOR

Chris Van Denburg

OFFICE MANAGER

Claudette Crawford

OFFICE ASSISTANT

Manuel Pavón

INFORMATION TECHNOLOGY

Adam Bolt

CORPORATION COUNSEL

Kevin F. Saer, Esq.
Davis, Wright, and Tremaine


OF COUNSEL

Lawrence Ross, Esq.
Bressler, Amery, and Ross

ACCOUNTANT

James Kiriakos, CPA
Pegg & Pegg

CNS Spectrums' editorial mission is to address relevant neuropsychiatric topics, including the prevalence of comorbid diseases among patients, and reports that emphasize the profound diagnostic and physiologic connections made within the neurologic and psychiatric fields. It serves as a resource to psychiatrists and neurologists seeking to understand and treat disturbances of cognition, emotion, and behavior as a direct consequence of central nervous system disease, illness, or trauma.



Something extra

...approximately
1/3 more
patients got
their life back

In a pooled analysis of over 2,000 patients, against leading SSRIs (fluoxetine, paroxetine, fluvoxamine),

EFFEXOR XR/EFFEXOR offered something extra—
in depression, remission* of symptoms in approximately 1/3 more patients.¹

Remission of symptoms is a first step on the road to recovery.²

***Remission is defined as minimal or no symptoms (HAM-D ≤7).¹**

Indicated in Depression and Generalized Anxiety Disorder

ONCE-DAILY
VENLAFAXINE HCl
EFFEXOR[®] XR EXTENDED
RELEASE CAPSULES

EFFEXOR XR is contraindicated in patients taking monoamine oxidase inhibitors (MAOIs). EFFEXOR XR should not be used in combination with an MAOI or within at least 14 days of discontinuing treatment with an MAOI; at least 7 days should be allowed after stopping EFFEXOR XR before starting an MAOI.

The most common adverse events reported in EFFEXOR XR placebo-controlled depression trials (incidence $\geq 10\%$ and $\geq 2\times$ that of placebo) were nausea, dizziness, somnolence, delayed ejaculation, sweating, dry mouth, and nervousness; and in GAD trials were nausea, dry mouth, insomnia, delayed ejaculation, anorexia, constipation, nervousness, and sweating.

Treatment with venlafaxine is associated with sustained increases in blood pressure (BP) in some patients. Three percent of EFFEXOR XR patients in depression studies (doses of 75 to 375 mg/day) and 0.5% in GAD studies (doses of 37.5 to 225 mg/day) had sustained BP elevations. Less than 1% discontinued treatment because of elevated BP. Regular BP monitoring is recommended.

Patients should not be abruptly discontinued from antidepressant medication, including EFFEXOR XR. See the Dosage and Administration section of the Prescribing Information.

References: 1. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. *Br J Psychiatry*. 2001;178:234-241.

2. Kupfer DJ. Long-term treatment of depression. *J Clin Psychiatry*. 1991;52(5, suppl):28-34.

Please see brief summary of Prescribing Information on adjacent page.

Visit us at www.EFFEXORXR.com

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

February 2003
Volume 8 - Number 2

Feature Articles

92 Introduction: Psychiatric Comorbidity and Pharmacotherapy in Sleep Disorders

By Angelos Halaris, MD, PhD

REVIEW

102 A Review of Common Sleep Disorders

By Allen C. Richert, MD, and Alp Sinan Baran, MD

ORIGINAL RESEARCH

114 Psychological Status and Levels of Sleepiness-Alertness Among Patients With Insomnia

By Leon D. Rosenthal, MD, and Renata M. Meixner, BA

REVIEW

120 Narcolepsy: Differential Diagnosis or Etiology in Some Cases of Bipolar Disorder and Schizophrenia?

By Alan B. Douglass, MD, FRCPC

REVIEW

128 Obstructive Sleep Apnea and Depression

By Alp Sinan Baran, MD, and Allen C. Richert, MD

REVIEW

135 Rhythmic Movement Disorder in Children

By Timothy F. Hoban, MD

ORIGINAL RESEARCH

139 Melatonin and Jet Lag Syndrome: Experimental Model and Clinical Implications

By Gregory F. Oxenkrug, MD, PhD, and Pura J. Requintina, PhD

CNS Spectrums is an *Index Medicus* journal and is available on MEDLINE. It is also indexed by DIALOG, EMBASE/Excerpta Medica, Lexis-Nexis, OVID, and SilverPlatter. *CNS Spectrums* is the official journal of the International Neuropsychiatric Association with members in 30 countries.

CNS Spectrums
(ISSN 1092-8529)

is published monthly by
MBL Communications, Inc.
333 Hudson Street, 7th Floor
New York, NY 10013

One year subscription rates:
domestic \$120;
foreign \$185;
in-training \$75.

For subscriptions:
Fax 212-328-0600
or visit our Web site:
www.cnspectrums.com

Postmaster:
Send address changes to
CNS Spectrums
c/o PPS Medical Marketing Group
264 Passaic Avenue
Fairfield, NJ 07004-2595

CNS SPECTRUMS®

The International Journal of Neuropsychiatric Medicine

Table of Contents

February 2003
Volume 8 - Number 2

Departments/Monthly Columns

CNS DIGEST

84 In the Journal of February 2003

- *A Comprehensive Look at Sleep Disorders*
- *Psychological Variations in Patients With Insomnia*
- *Narcolepsy's Possible Comorbidity With Bipolar Disorder and Schizophrenia*
- *Depression and its Association With Obstructive Sleep Apnea*
- *Occurrence of Rhythmic Movement Disorder in Children*
- *Jet Lag, Circadian Rhythms, and Rats*

POINT & COMMENTARY

85 Overlooked and Taken for Granted: Sleep Disorders and Sleep Medicine

By Jack M. Gorman, MD

CNS REPORTS

89 News From the Fields of Neuroscience

- *Attention-deficit/Hyperactivity Disorder and Lifelong Substance Abuse Not Correlated*
- *Brain's Reading Network Formed Earlier Than Previously Thought*
- *FDA Approves Antiepileptic for Children*
- *Hippocampus and its Components Culprit Behind Inability to Match Name With Face*

Request for Applications: National Institute on Drug Abuse—Stress and Drug Abuse Epidemiology, Etiology, Prevention, and Treatment

NEUROLOGY OF BEHAVIOR

91 Novel Insights Into Neuropsychiatry

By Michael Trimble, MD, FRCP, FRPsych

CONTINUING MEDICAL EDUCATION

149 The CME quiz on sleep disorders is accredited by Mount Sinai School of Medicine for 3 credit hours in Category 1.

INDICES

152 By subject and author

For editorial inquiries, please fax us at 212-328-0600 or E-mail us at jrr@mblcommunications.com.

For advertising inquiries, please fax us at 212-328-0600 or E-mail us at dlb@mblcommunications.com.

For reprint services, please contact: Marsha Fogler, Sheridan Reprints, at 1-800-482-1450

Opinions and views expressed by authors are their own and do not necessarily reflect the views of the publisher, MBL Communications, Inc., or the editorial advisory board. Advertisements in *CNS Spectrums* are accepted on the basis of adherence to ethical medical standards, but acceptance does not imply endorsement by *CNS Spectrums* or the publisher.

CNS Spectrums® is a registered trademark of *CNS Spectrums*, LLC, New York, NY.

Permission to reproduce articles in whole or part must be obtained in writing from the publisher.

Copyright ©2003 by MBL Communications, Inc. All rights reserved. Printed in the United States.



Audit Bureau of Circulations
MEMBER SINCE 2001


NOW AVAILABLE


New

ABILIFY™
(aripiprazole)

A new road is open.

Visit www.abilify.com for more information.

 Bristol-Myers Squibb Company

 Otsuka America Pharmaceutical, Inc.

© 2002 Otsuka Pharmaceutical Co., Ltd., Tokyo, Japan D6-K0009 A4055/09-02 Printed in USA